Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

4(67%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

33%

Ph phase_2

50%

Ph phase_3

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

Phase 2Efficacy & side effects

3(50.0%)

Phase 3Large-scale testing

1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(1)

Terminated(1)

Detailed Status

Active, not recruiting4

Completed1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 12 (33.3%)

Phase 23 (50.0%)

Phase 31 (16.7%)

Trials by Status

active_not_recruiting467%

completed117%

withdrawn117%

Recent Activity

4 active trials

Showing 5 of 6

active_not_recruitingphase_3

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

NCT06635824

active_not_recruitingphase_2

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

NCT06984328

active_not_recruitingphase_2

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

NCT05117242

active_not_recruitingphase_1

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

NCT03917381

completedphase_1

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

NCT04937153

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT06635824Phase 3

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

Active Not Recruiting

NCT06984328Phase 2

Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Active Not Recruiting

NCT05117242Phase 2

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Active Not Recruiting

NCT03917381Phase 1

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Active Not Recruiting

NCT04937153Phase 1

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Completed

NCT06046274Phase 2

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer